固定疗程伊布替尼联合维奈克拉治疗初治慢性淋巴细胞白血病,对残留病灶者以MRD指导伊布替尼联合奥妥珠单抗强化:HOVON 158/NEXT STEP多中心、开放标签、2期试验主要分析
HOVON158/NEXT STEP是一项在荷兰和丹麦17家医院开展的开放标签2期研究,评估固定疗程伊布替尼联合维奈克拉后仅对残留病灶者以伊布替尼联合奥妥珠单抗强化的策略。85例入组、84例合格,强化组55例中33例(60%;90% CI 48-71)在强化结束3个月达骨髓uMRD4完全缓解或伴不完全计数恢复的完全缓解;作者认为该策略值得进一步研究。
要点
- 伊布替尼联合维奈克拉15个28天周期后,达uMRD4完全缓解者停药观察,其余接受伊布替尼联合奥妥珠单抗强化6周期。
- 强化组55例中33例(60%;90% CI 48-71)在强化结束3个月达骨髓uMRD4完全缓解或伴不完全计数恢复的完全缓解。
- 伊布替尼联合维奈克拉期间最常见3-4级不良事件为中性粒细胞减少(36/84,43%)和感染(19/84,23%)。
核心结论
- 以疗效和MRD指导的强化策略使残留病灶者的缓解加深,并使早期应答者免于进一步治疗。
- 作者认为该策略作为固定疗程三药联合治疗的替代方案值得进一步研究。
研究设计与样本
- HOVON158/NEXT STEP为开放标签2期研究,在荷兰和丹麦17家医院开展。
- 入组年龄≥18岁、既往未治疗、按国际慢性淋巴细胞白血病工作组标准需要治疗、ECOG体能状态0、1或2的慢性淋巴细胞白血病患者。
- 主要终点为伊布替尼联合奥妥珠单抗强化结束后3个月时,在伊布替尼联合维奈克拉后未达完全缓解或MRD可检测者中的骨髓uMRD4完全缓解或伴不完全计数恢复的完全缓解,按改良意向治疗原则排除回顾性判定不合格者后分析。
- 安全性分析纳入至少接受一剂研究药物的所有参与者。
- 研究于2020年12月29日至2021年8月20日入组85例,84例合格(56例男性、28例女性)。
主要发现
- 强化组55例(37例男性、18例女性),观察组17例(11例男性、6例女性)。
- 伊布替尼联合奥妥珠单抗治疗结束3个月后,55例中33例(60%;90% CI 48-71)达骨髓uMRD4完全缓解或伴不完全计数恢复的完全缓解。
- 伊布替尼联合维奈克拉治疗期间最常见3-4级不良事件为中性粒细胞减少(36/84,43%)和感染(19/84,23%)。
- 伊布替尼联合奥妥珠单抗治疗期间最常见3-4级不良事件为中性粒细胞减少和血小板减少(5/52,10%)及神经系统疾病(4/52,8%)。
- 伊布替尼联合维奈克拉组28例(33%)发生严重不良事件,伊布替尼联合奥妥珠单抗组7例(13%)发生严重不良事件;无治疗相关死亡。
关键数值与推荐
- 伊布替尼口服420 mg每日一次,联合维奈克拉口服(自第4周期起5周递增至400 mg每日一次),共15个28天周期。
- 伊布替尼联合维奈克拉后达完全缓解或伴不完全计数恢复的完全缓解且骨髓uMRD4(<10^-4)者停药。
- 其余参与者接受额外6周期伊布替尼联合奥妥珠单抗静脉给药(第1周期第1、2、8、15天及第2-6周期第1天,1000 mg)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Triplet regimens combining a Bruton's tyrosine kinase inhibitor, B-cell lymphoma 2 inhibitor, and anti-CD20 antibody are among the most effective first-line treatments for chronic lymphocytic leukaemia, but come with substantial toxicity. We investigated whether fixed-duration ibrutinib plus venetoclax, followed by ibrutinib plus obinutuzumab intensification for individuals with residual disease only, could offer a more tailored and less toxic alternative. METHODS: HOVON158/NEXT STEP was an open-label, phase 2 study at 17 hospitals in the Netherlands and Denmark. Eligible participants were aged 18 years or older with previously untreated chronic lymphocytic leukaemia, requiring treatment according to the International Workshop on Chronic Lymphocytic Leukemia, with an Eastern Cooperative Oncology Group performance status of 0, 1, or 2. Participants with complete remission or complete remission with incomplete count recovery and undetectable measurable residual disease (<10-4 uMRD4) in bone marrow after 15 28-day cycles of oral ibrutinib (420 mg once daily) plus oral venetoclax (5-weekly ramp-up from cycle 4 up to 400 mg once daily) discontinued treatment; all other participants received an additional six cycles of ibrutinib plus obinutuzumab intravenously (1000 mg on days 1, 2, 8, and 15 of cycle 1 and day 1 of cycles 2-6). The primary endpoint was bone marrow uMRD4 complete remission or complete remission with incomplete count recovery 3 months after the end of intensification with ibrutinib plus obinutuzumab in participants who were not in complete remission or who had detectable measurable residual disease (MRD) on ibrutinib plus venetoclax, and analysed according to the modified intention-to-treat principle excluding participants retrospectively deemed ineligible. All participants who received at least one dose of the study drug were included in the safety assessment. This report is the primary endpoint analysis of this trial, which is registered at ClinicalTrials.gov, NCT04639362, and is ongoing. FINDINGS: Between Dec 29, 2020, and Aug 20, 2021, 85 participants were enrolled, 84 of whom were eligible (56 male and 28 female). The intensification group consisted of 55 participants (37 male and 18 female) and the observation group consisted of 17 participants (11 male and six female). 3 months after the end of ibrutinib plus obinutuzumab treatment, 33 (60%; 90% CI 48-71) of 55 participants had bone marrow uMRD4 complete remission or complete remission with incomplete count recovery. The most common grade 3-4 adverse events during ibrutinib plus venetoclax treatment were neutropenia (36 [43%] of 84 participants) and infections (19 [23%] participants), and the most common during ibrutinib plus obinutuzumab treatment were neutropenia and thrombocytopenia (five [10%] of 52 participants) and nervous system disorders (4 [8%] participants). Serious adverse events occurred in 28 (33%) participants receiving ibrutinib plus venetoclax and seven (13%) participants receiving ibrutinib plus obinutuzumab. There were no treatment-related deaths. INTERPRETATION: An intensification strategy guided by response and MRD deepened remissions in individuals with residual disease and spared early responders further treatment. This approach merits further study as an alternative to fixed-duration triplet therapy. FUNDING: Janssen. TRANSLATION: For the Dutch translation of the abstract see Supplementary Materials section.
引用
- Kater AP, Kersting S, Dubois JM, et al. Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial. Lancet Haematol. 2025. PMID: 41338862. doi:10.1016/S2352-3026(25)00288-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。